Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
The management of HER-2-positive breast cancer has improved significantly with the use of targeted agents to the HER-2 signaling pathway. Despite the improved survival achieved with the use of trastuzumab and chemotherapy in both the adjuvant and metastatic setting, patients may still recur or progr...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-09-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834016656494 |